Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Long pentraxin-3 inhibits epithelial-mesenchymal transition in melanoma cells.

Ronca R, Di Salle E, Giacomini A, Leali D, Alessi P, Coltrini D, Ravelli C, Matarazzo S, Ribatti D, Vermi W, Presta M.

Mol Cancer Ther. 2013 Dec;12(12):2760-71. doi: 10.1158/1535-7163.MCT-13-0487. Epub 2013 Oct 15.

2.

Inhibition of angiogenesis by β-galactosylceramidase deficiency in globoid cell leukodystrophy.

Belleri M, Ronca R, Coltrini D, Nico B, Ribatti D, Poliani PL, Giacomini A, Alessi P, Marchesini S, Santos MB, Bongarzone ER, Presta M.

Brain. 2013 Sep;136(Pt 9):2859-75. doi: 10.1093/brain/awt215.

3.

Long pentraxin-3 as an epithelial-stromal fibroblast growth factor-targeting inhibitor in prostate cancer.

Ronca R, Alessi P, Coltrini D, Di Salle E, Giacomini A, Leali D, Corsini M, Belleri M, Tobia C, Garlanda C, Bonomi E, Tardanico R, Vermi W, Presta M.

J Pathol. 2013 Jun;230(2):228-38. doi: 10.1002/path.4181.

PMID:
23424081
4.

Long pentraxin-3 inhibits FGF8b-dependent angiogenesis and growth of steroid hormone-regulated tumors.

Leali D, Alessi P, Coltrini D, Ronca R, Corsini M, Nardo G, Indraccolo S, Presta M.

Mol Cancer Ther. 2011 Sep;10(9):1600-10. doi: 10.1158/1535-7163.MCT-11-0286. Epub 2011 Jul 15.

5.

Antiangiogenic activity of a neutralizing human single-chain antibody fragment against fibroblast growth factor receptor 1.

Ronca R, Benzoni P, Leali D, Urbinati C, Belleri M, Corsini M, Alessi P, Coltrini D, Calza S, Presta M, Dell'Era P.

Mol Cancer Ther. 2010 Dec;9(12):3244-53. doi: 10.1158/1535-7163.MCT-10-0417. Epub 2010 Oct 12.

6.

New automated and high-throughput quantitative analysis of urinary ketones by multifiber exchange-solid phase microextraction coupled to fast gas chromatography/negative chemical-electron ionization/mass spectrometry.

Pacenti M, Dugheri S, Traldi P, Degli Esposti F, Perchiazzi N, Franchi E, Calamante M, Kikic I, Alessi P, Bonacchi A, Salvadori E, Arcangeli G, Cupelli V.

J Autom Methods Manag Chem. 2010;2010:972926. doi: 10.1155/2010/972926. Epub 2010 Jun 15.

7.

Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist.

Alessi P, Leali D, Camozzi M, Cantelmo A, Albini A, Presta M.

Eur Cytokine Netw. 2009 Dec;20(4):225-34. doi: 10.1684/ecn.2009.0175. Review.

8.

IL-7 is superior to IL-2 for ex vivo expansion of tumour-specific CD4(+) T cells.

Caserta S, Alessi P, Basso V, Mondino A.

Eur J Immunol. 2010 Feb;40(2):470-9. doi: 10.1002/eji.200939801.

9.

Fibroblast growth factor-2 antagonist and antiangiogenic activity of long-pentraxin 3-derived synthetic peptides.

Leali D, Alessi P, Coltrini D, Rusnati M, Zetta L, Presta M.

Curr Pharm Des. 2009;15(30):3577-89. Review.

PMID:
19860702
10.

Delivering cytokines at tumor site: The immunocytokine-conjugated anti-EDB-fibronectin antibody case.

Ronca R, Sozzani S, Presta M, Alessi P.

Immunobiology. 2009;214(9-10):800-10. doi: 10.1016/j.imbio.2009.06.005. Epub 2009 Jul 21. Review.

PMID:
19625102
11.

alphavbeta3 Integrin-dependent antiangiogenic activity of resveratrol stereoisomers.

Belleri M, Ribatti D, Savio M, Stivala LA, Forti L, Tanghetti E, Alessi P, Coltrini D, Bugatti A, Mitola S, Nicoli S, Vannini V, Presta M.

Mol Cancer Ther. 2008 Dec;7(12):3761-70. doi: 10.1158/1535-7163.MCT-07-2351.

12.

The preparation of pellets containing non-ionic surfactants by extrusion/spheronization.

Podczeck F, Alessi P, Newton JM.

Int J Pharm. 2008 Sep 1;361(1-2):33-40. doi: 10.1016/j.ijpharm.2008.05.008. Epub 2008 May 15.

PMID:
18571347
13.

Determination of organic acids in urine by solid-phase microextraction and gas chromatography-ion trap tandem mass spectrometry previous 'in sample' derivatization with trimethyloxonium tetrafluoroborate.

Pacenti M, Dugheri S, Villanelli F, Bartolucci G, Calamai L, Boccalon P, Arcangeli G, Vecchione F, Alessi P, Kikic I, Cupelli V.

Biomed Chromatogr. 2008 Oct;22(10):1155-63. doi: 10.1002/bmc.1039.

PMID:
18506742
14.

Synthetic CD4+ T cell-targeted antigen-presenting cells elicit protective antitumor responses.

Caserta S, Alessi P, Guarnerio J, Basso V, Mondino A.

Cancer Res. 2008 Apr 15;68(8):3010-8. doi: 10.1158/0008-5472.CAN-07-5796.

15.

Supercritical antisolvent precipitation of nimesulide: preliminary experiments.

Moneghini M, Perissutti B, Vecchione F, Kikic I, Alessi P, Cortesi A, Princivalle F.

Curr Drug Deliv. 2007 Jul;4(3):241-8.

PMID:
17627498
16.

Uptake of 18F-Fluorocholine, 18F-FET, and 18F-FDG in C6 gliomas and correlation with 131I-SIP(L19), a marker of angiogenesis.

Wyss MT, Spaeth N, Biollaz G, Pahnke J, Alessi P, Trachsel E, Treyer V, Weber B, Neri D, Buck A.

J Nucl Med. 2007 Apr;48(4):608-14.

17.

Selective occlusion of tumor blood vessels by targeted delivery of an antibody-photosensitizer conjugate.

Fabbrini M, Trachsel E, Soldani P, Bindi S, Alessi P, Bracci L, Kosmehl H, Zardi L, Neri D, Neri P.

Int J Cancer. 2006 Apr 1;118(7):1805-13.

18.

Molecular imaging of atherosclerotic plaques using a human antibody against the extra-domain B of fibronectin.

Matter CM, Schuler PK, Alessi P, Meier P, Ricci R, Zhang D, Halin C, Castellani P, Zardi L, Hofer CK, Montani M, Neri D, Lüscher TF.

Circ Res. 2004 Dec 10;95(12):1225-33. Epub 2004 Nov 11.

PMID:
15539632
19.

Engineering a thermostable human prolyl endopeptidase for antibody-directed enzyme prodrug therapy.

Heinis C, Alessi P, Neri D.

Biochemistry. 2004 May 25;43(20):6293-303.

PMID:
15147213
20.

Molecular targeting of angiogenesis.

Alessi P, Ebbinghaus C, Neri D.

Biochim Biophys Acta. 2004 Mar 4;1654(1):39-49. Review.

PMID:
14984766
21.

Study of the solid state of carbamazepine after processing with gas anti-solvent technique.

Moneghini M, Kikic I, Voinovich D, Perissutti B, Alessi P, Cortesi A, Princivalle F, Solinas D.

Eur J Pharm Biopharm. 2003 Sep;56(2):281-9.

PMID:
12957643
22.

'Don't eat that hamburger!': examining foodborne illnesses.

Alessi PJ.

J Am Osteopath Assoc. 1997 Oct;97(10):576, 579. No abstract available.

PMID:
9357229
23.

Eustrongylidiasis--a parasitic infection acquired by eating live minnows.

Narr LL, O'Donnell JG, Libster B, Alessi P, Abraham D.

J Am Osteopath Assoc. 1996 Jul;96(7):400-2.

PMID:
8758872
24.

Oral ofloxacin for the treatment of acute bacterial pneumonia: use of a nontraditional protocol to compare experimental therapy with "usual care" in a multicenter clinical trial.

Sanders WE Jr, Morris JF, Alessi P, Makris AT, McCloskey RV, Trenholme GM, Iannini P, Bittner MJ.

Am J Med. 1991 Sep;91(3):261-6.

PMID:
1892146
25.

Ofloxacin use in a geriatric population.

Nicolle LE, Degelau J, Alessi P, Cullison J, Meyers B.

Chemotherapy. 1991;37 Suppl 1:49-54.

PMID:
2049965
26.

A clinical approach to the choice of antimicrobial agents. Case number 14: Acute pharyngitis.

Alessi PJ, Van Arsdall JA 2nd, Raff MJ, Melo JC.

J Ky Med Assoc. 1980 Feb;78(2):79-81. No abstract available.

PMID:
7359017
27.

[Data on risks in the process of electric arc welding].

Gobbato F, Alessi P.

Lav Um. 1972 Nov;24(6):170-84. Italian. No abstract available.

PMID:
4680387

Supplemental Content

Loading ...
Support Center